Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6


Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure.

Kekow J, Mueller-Ladner U, Schulze-Koops H.

Biologics. 2012;6:191-9. doi: 10.2147/BTT.S32244. Epub 2012 Jul 2.


Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature.

Scrivo R, Conti F, Spinelli FR, Truglia S, Magrini L, Di Franco M, Ceccarelli F, Valesini G.

Reumatismo. 2009 Apr-Jun;61(2):107-17. Review.


Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.


Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G.

Am J Clin Dermatol. 2008;9(1):1-14. Review. Erratum in: Am J Clin Dermatol. 2008;9(5):347.


Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.

Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R.

Pharmacotherapy. 2010 Apr;30(4):339-53. doi: 10.1592/phco.30.4.339. Review.


Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence.

Costa L, Perricone C, Chimenti MS, Del Puente A, Caso P, Peluso R, Bottiglieri P, Scarpa R, Caso F.

Drugs R D. 2017 Dec;17(4):509-522. doi: 10.1007/s40268-017-0215-7. Review.

Supplemental Content

Support Center